PTEN hamartoma tumor syndromes

Area of Science:

• Genetics and Oncology
• Cellular Biology
• Rare Diseases

Background:

• PTEN hamartoma tumor syndromes (PHTS) are rare genetic disorders caused by germline mutations in the PTEN tumor suppressor gene.
• These syndromes lead to cellular overgrowth and benign hamartomas in various organs, with Cowden syndrome (CS) increasing risks for breast, thyroid, and endometrial cancers.
• PTEN normally inhibits the PI3K/Akt/mTOR pathway, crucial for cell survival and growth.

Purpose of the Study:

• To summarize the clinical characteristics and biological underpinnings of PTEN hamartoma tumor syndromes (PHTS).
• To highlight the importance of early screening and surveillance for associated malignancies in patients with PHTS, particularly Cowden syndrome.
• To explore the therapeutic potential of PI3K/Akt/mTOR pathway inhibitors for PHTS patients.

Main Methods:

• Review of existing literature on PTEN hamartoma tumor syndromes (PHTS) and Cowden syndrome (CS).
• Analysis of the role of PTEN in regulating the PI3K/Akt/mTOR pathway.
• Examination of current clinical management strategies and emerging therapeutic targets.

Main Results:

• Germline PTEN mutations drive PHTS, characterized by hamartomas and increased cancer susceptibility.
• Loss of PTEN function activates the PI3K/Akt/mTOR pathway, promoting cellular proliferation and survival.
• Current management focuses on surveillance and preventive care for associated cancers.

Conclusions:

• PHTS requires vigilant clinical management including screening and surveillance for malignancies.
• The PI3K/Akt/mTOR pathway is a key target for understanding PHTS pathogenesis.
• Inhibitors of the PI3K/Akt/mTOR pathway represent a promising avenue for future medical therapies for PHTS patients, addressing a current lack of treatment options.